MEDICINA
DEPARTAMENTO
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (24)
2024
-
Differences in survival and recurrence of colorectal cancer by stage across population-based European registries
International Journal of Cancer, Vol. 155, Núm. 5, pp. 807-815
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
-
Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2665-2678), 10.1007/s12094-023-03203-8)
Clinical and Translational Oncology
-
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041
-
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2665-2678
2021
-
Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study
Digestive and Liver Disease, Vol. 53, Núm. 5, pp. 639-645
2020
-
Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study
European Journal of Surgical Oncology, Vol. 46, Núm. 6, pp. 1151-1159
-
Hospital epidemics tracker (hepitracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers
JMIR Public Health and Surveillance, Vol. 6, Núm. 3
2019
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 459-466
2018
-
Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20 years
Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1289-1301
2017
-
Trends in net survival from prostate cancer in six European Latin countries: Results from the SUDCAN population-based study
European Journal of Cancer Prevention, Vol. 26, Núm. Trends in cancer net survival in six European Latin Countries: the SUDCAN study, pp. S114-S120
-
Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries
The Lancet Haematology, Vol. 4, Núm. 5, pp. e202-e217
2015
-
Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design
Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315
-
Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study
European Journal of Cancer, Vol. 51, Núm. 15, pp. 2206-2216
2014
-
Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project
Cancer Epidemiology, Vol. 38, Núm. 6, pp. 670-678
2013
-
Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project
European Journal of Cancer, Vol. 49, Núm. 11, pp. 2565-2578
2012
-
Carcinoma of endocrine organs: Results of the RARECARE project
European Journal of Cancer, Vol. 48, Núm. 13, pp. 1923-1931
-
Embryonal cancers in Europe
European Journal of Cancer, Vol. 48, Núm. 10, pp. 1425-1433
-
Epidemiology of glial and non-glial brain tumours in Europe
European Journal of Cancer, Vol. 48, Núm. 10, pp. 1532-1542